These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 20129576)
1. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and -9. Katsaros KM; Kastl SP; Zorn G; Maurer G; Wojta J; Huber K; Christ G; Speidl WS JACC Cardiovasc Interv; 2010 Jan; 3(1):90-7. PubMed ID: 20129576 [TBL] [Abstract][Full Text] [Related]
2. Angiographic and intravascular ultrasound follow up of paclitaxel- and sirolimus-eluting stent after poststent high-pressure balloon dilation: from the poststent optimal stent expansion trial. Park SM; Kim JS; Ko YG; Choi D; Hong MK; Jang Y; Kang WC; Ahn T; Kim BK; Oh SJ; Jeon DW; Yang JY Catheter Cardiovasc Interv; 2011 Jan; 77(1):15-21. PubMed ID: 20928842 [TBL] [Abstract][Full Text] [Related]
3. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials. Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555 [TBL] [Abstract][Full Text] [Related]
4. Active matrix metalloproteinases 3 and 9 are independently associated with coronary artery in-stent restenosis. Jones GT; Tarr GP; Phillips LV; Wilkins GT; van Rij AM; Williams MJ Atherosclerosis; 2009 Dec; 207(2):603-7. PubMed ID: 19576586 [TBL] [Abstract][Full Text] [Related]
5. Long-Term Outcomes After Treatment With a Paclitaxel-Coated Balloon Versus Balloon Angioplasty: Insights From the PEPCAD-DES Study (Treatment of Drug-eluting Stent [DES] In-Stent Restenosis With SeQuent Please Paclitaxel-Coated Percutaneous Transluminal Coronary Angioplasty [PTCA] Catheter). Rittger H; Waliszewski M; Brachmann J; Hohenforst-Schmidt W; Ohlow M; Brugger A; Thiele H; Birkemeyer R; Kurowski V; Schlundt C; Zimmermann S; Lonke S; von Cranach M; Markovic S; Daniel WG; Achenbach S; Wöhrle J JACC Cardiovasc Interv; 2015 Nov; 8(13):1695-700. PubMed ID: 26476609 [TBL] [Abstract][Full Text] [Related]
6. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis. Ishii H; Toriyama T; Aoyama T; Takahashi H; Amano T; Hayashi M; Tanaka M; Kawamura Y; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T Circ Cardiovasc Interv; 2009 Dec; 2(6):513-8. PubMed ID: 20031768 [TBL] [Abstract][Full Text] [Related]
7. Paclitaxel-coated balloon for the treatment of drug-eluting stent restenosis: subanalysis results from the Valentines I trial. Loh JP; Stella PR; Sangiorgi G; Silber S; Stahnke S; von Strandmann RP; Torguson R; Waksman R Cardiovasc Revasc Med; 2014 Jan; 15(1):23-8. PubMed ID: 24444473 [TBL] [Abstract][Full Text] [Related]
8. Management of distal/bifurcation left main restenosis after drug eluting stents implantation: single center experience. Rigatelli G; Cardaioli P; Dell'Avvocata F; Giordan M; Vassilev D; Fraccaro C; Roncon L; Faggian G Cardiovasc Revasc Med; 2014 Mar; 15(2):76-9. PubMed ID: 24560299 [TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-eluting balloon versus everolimus-eluting stent for treatment of drug-eluting stent restenosis. Almalla M; Schröder J; Pross V; Marx N; Hoffmann R Catheter Cardiovasc Interv; 2014 May; 83(6):881-7. PubMed ID: 23765557 [TBL] [Abstract][Full Text] [Related]
10. Significant association of coronary stent fracture with in-stent restenosis in sirolimus-eluting stents. Kim JS; Lee SY; Lee JM; Yoon YW; Ahn CM; Kim MH; Min PK; Ko YG; Hong BK; Choi D; Kwon HM; Jang Y; Shim WH Coron Artery Dis; 2009 Jan; 20(1):59-63. PubMed ID: 19008765 [TBL] [Abstract][Full Text] [Related]
11. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents. Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783 [TBL] [Abstract][Full Text] [Related]
12. Long-term clinical and angiographic outcomes after implantation of sirolimus-eluting stents with a "modified mini-crush" technique in coronary bifurcation lesions. Yang HM; Tahk SJ; Woo SI; Lim HS; Choi BJ; Choi SY; Yoon MH; Park JS; Zheng M; Hwang GS; Kang SJ; Shin JH Catheter Cardiovasc Interv; 2009 Jul; 74(1):76-84. PubMed ID: 19360861 [TBL] [Abstract][Full Text] [Related]
13. Impact of lesion calcification on clinical and angiographic outcome after sirolimus-eluting stent implantation in real-world patients. Kawaguchi R; Tsurugaya H; Hoshizaki H; Toyama T; Oshima S; Taniguchi K Cardiovasc Revasc Med; 2008; 9(1):2-8. PubMed ID: 18206630 [TBL] [Abstract][Full Text] [Related]
14. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147 [TBL] [Abstract][Full Text] [Related]
15. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. Byrne RA; Iijima R; Mehilli J; Pinieck S; Bruskina O; Schömig A; Kastrati A JACC Cardiovasc Interv; 2009 Apr; 2(4):291-9. PubMed ID: 19463439 [TBL] [Abstract][Full Text] [Related]
16. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent. Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247 [TBL] [Abstract][Full Text] [Related]
17. A prospective randomised study using optical coherence tomography to assess endothelial coverage and neointimal proliferation at 6-months after implantation of a coronary everolimus-eluting stent compared with a bare metal stent postdilated with a paclitaxel-eluting balloon (OCTOPUS Trial): rationale, design and methods. Poerner TC; Otto S; Gassdorf J; Janiak F; Danzer C; Ferrari M; Figulla HR EuroIntervention; 2011 May; 7 Suppl K():K93-9. PubMed ID: 22027737 [TBL] [Abstract][Full Text] [Related]
18. Third in-stent restenosis in sirolimus eluting stents: predictors of the next restenosis. Ozawa M; Okamura A; Date M; Higuchi Y; Nagai H; Shibuya M; Ryusuke K; Inoue K; Koyama Y; Iwakura K; Fujii K Catheter Cardiovasc Interv; 2012 Jan; 79(1):91-6. PubMed ID: 21452246 [TBL] [Abstract][Full Text] [Related]
19. In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. Novack V; Cutlip D; Kleiman N; Pencina M; Mauri L; Yen CH; Berger P; Goldberg S; Kellett M; Waksman R; Hong M; Raizner AE; Cohen DJ JACC Cardiovasc Interv; 2009 Aug; 2(8):767-75. PubMed ID: 19695546 [TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis: the three-year results of the PEPCAD II ISR study. Unverdorben M; Vallbracht C; Cremers B; Heuer H; Hengstenberg C; Maikowski C; Werner GS; Antoni D; Kleber FX; Bocksch W; Leschke M; Ackermann H; Boxberger M; Speck U; Degenhardt R; Scheller B EuroIntervention; 2015 Dec; 11(8):926-34. PubMed ID: 25169589 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]